Praxis Precision Medicines (PRAX) Revenue & Revenue Breakdown
Praxis Precision Medicines Revenue Highlights
Latest Revenue (Y)
$2.45M
Latest Revenue (Q)
$357.00K
Main Segment (Y)
License
Praxis Precision Medicines Revenue by Period
Praxis Precision Medicines Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $2.45M | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Praxis Precision Medicines Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $357.00K | -17.17% |
2024-03-31 | $431.00K | -16.31% |
2023-12-31 | $515.00K | 10.04% |
2023-09-30 | $468.00K | -40.08% |
2023-06-30 | $781.00K | 14.35% |
2023-03-31 | $683.00K | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | - |
Praxis Precision Medicines Revenue Breakdown
Praxis Precision Medicines Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 |
---|---|---|
License | $2.40M | $98.50M |
Quarterly Revenue by Product
Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 |
---|---|---|---|---|---|---|
License | $400.00K | $400.00K | $400.00K | $500.00K | $800.00K | $700.00K |
Praxis Precision Medicines Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
MOLN | Molecular Partners | $7.04M | $2.74M |
CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
HCWB | HCW Biologics | $2.84M | $618.85K |
PRAX | Praxis Precision Medicines | $2.45M | $357.00K |
ANEB | Anebulo Pharmaceuticals | - | - |
CGEM | Cullinan Oncology | - | - |
IMRX | Immuneering | - | - |
ANTX | AN2 Therapeutics | - | - |
PHVS | Pharvaris | - | - |
DYN | Dyne Therapeutics | - | - |
ELYM | Eliem Therapeutics | - | - |
PMVP | PMV Pharmaceuticals | - | - |
MLYS | Mineralys Therapeutics | - | - |
ELVN | Enliven Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
PEPG | PepGen | - | - |
PRAX Revenue FAQ
What is Praxis Precision Medicines’s yearly revenue?
Praxis Precision Medicines's yearly revenue for 2023 was $2.45M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. PRAX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Praxis Precision Medicines’s quarterly revenue?
Praxis Precision Medicines's quarterly revenue for Q2 2024 was $357K, a -17.17% decrease from the previous quarter (Q1 2024), and a -54.29% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $431K, a -16.31% decrease from the previous quarter (Q4 2023), and a -36.90% decrease year-over-year (Q1 2023). PRAX's quarterly revenue for Q4 2023 was $515K, a 10.04% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Praxis Precision Medicines’s revenue growth rate?
Praxis Precision Medicines's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.
What are Praxis Precision Medicines’s revenue streams?
Praxis Precision Medicines's revenue streams in c 23 are License
What is Praxis Precision Medicines’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Praxis Precision Medicines was License. This segment made a revenue of $2.4M, representing 100.00% of the company's total revenue.